58 related articles for article (PubMed ID: 6151361)
1. Pharmacokinetics of 3-[Bis(2-hydroxyethyl)amino]acetophenone-(4,5- diphenyloxazol-2-yl)hydrazone (ZIMET 98/69) in mice.
Amlacher R; Ulbricht H
Acta Virol; 1984 Sep; 28(5):445. PubMed ID: 6151361
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of 3-[bis(2-hydroxyethyl)amino]acetophenone-(4,5-diphenyloxazol-2-yl) hydrazone (ZIMET 98/69) after oral administration to mice.
Amlacher R; Ulbricht H
Pharmazie; 1985 May; 40(5):338-40. PubMed ID: 2863831
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 3-[bis(2-hydroxyethyl)amino]acetophenone [4,5-diphenyloxazolyl-(2)]hydrazone (ZIMET 98/69) in rats.
Amlacher R; Horn U; Kramarczyk K; Ulbricht H; Hoffmann H
Pharmazie; 1982 Jan; 37(1):33-5. PubMed ID: 6122223
[TBL] [Abstract][Full Text] [Related]
4. Sex- and age-related mouse toxicity and disposition of the amino acid antitumor agent, acivicin.
McGovren JP; Neil GL; Chan PJ; Stewart JC
J Pharmacol Exp Ther; 1981 Mar; 216(3):433-40. PubMed ID: 7205622
[TBL] [Abstract][Full Text] [Related]
5. The immunosuppressive effect of beta-[1-phenyl-5-bis(beta-chloroethyl)-aminobenzimidazolyl-(2)]-DL-alanine (ZIMET 3164) on cell-mediated immunity in mice.
Heinecke H; Ozegowski W
Allerg Immunol (Leipz); 1980; 26(1):41-5. PubMed ID: 6447447
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
8. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
9. A study of peroxyoxalate-chemiluminescence of 4,4'-bis{[4,6-bis (2-hydroxyethyl)amino-1,3,5-triazin-2-yl]amino}stilbene-2,2'-disulfonic acid-disodium salt as a novel blue fluorescer.
Shamsipur M; Yeganeh-Faal A; Chaichi MJ; Tajbakhsh M; Parach A
Spectrochim Acta A Mol Biomol Spectrosc; 2007 Mar; 66(3):546-51. PubMed ID: 16859973
[TBL] [Abstract][Full Text] [Related]
10. [Fate of free bis(beta-chloroethyl)-amine in blood serum].
Rauen HM; Norpoth K; Kramer KP
Arzneimittelforschung; 1965 Sep; 15(9):1048-51. PubMed ID: 5898691
[No Abstract] [Full Text] [Related]
11. Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists.
Betts A; Atkinson F; Gardner I; Fox D; Webster R; Beaumont K; Morgan P
Drug Metab Dispos; 2007 Aug; 35(8):1435-45. PubMed ID: 17502340
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological disposition of 1,4-bis (2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione diacetate in the dog.
Lu K; Loo TL
Cancer Res; 1980 May; 40(5):1427-30. PubMed ID: 7370981
[TBL] [Abstract][Full Text] [Related]
13. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
14. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
15. GABA and muscimol binding processes in CNS tissue culture preparations.
DeFeudis FV; Ossola L; Sarliève LL; Schmitt G; Rebel G; Varga V; Mandel P
Adv Biochem Psychopharmacol; 1981; 29():405-10. PubMed ID: 7257936
[No Abstract] [Full Text] [Related]
16. Effect of acute ethanol administration on toloxatone pharmacokinetics in rabbits.
Kaltenbach ML; Vistelle R; Hoizey G; Lamiable D; Zbierski L
Alcohol Clin Exp Res; 1999 May; 23(5):885-90. PubMed ID: 10371410
[TBL] [Abstract][Full Text] [Related]
17. Effect of murine strain on metabolic pathways of glucose production after brief or prolonged fasting.
Burgess SC; Jeffrey FM; Storey C; Milde A; Hausler N; Merritt ME; Mulder H; Holm C; Sherry AD; Malloy CR
Am J Physiol Endocrinol Metab; 2005 Jul; 289(1):E53-61. PubMed ID: 15797985
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Lauric Acid Diethanolamine Condensate (CAS NO. 120-40-1) in F344/N Rats and B6C3F1 Mice (Dermal Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Jul; 480():1-200. PubMed ID: 12571683
[TBL] [Abstract][Full Text] [Related]
19. Role of renal D-amino-acid oxidase in pharmacokinetics of D-leucine.
Hasegawa H; Matsukawa T; Shinohara Y; Konno R; Hashimoto T
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E160-5. PubMed ID: 15026304
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
